ALT Logo

Altimmune, Inc. (ALT) 

NASDAQ
Market Cap
$610.96M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
431 of 963
Rank in Industry
255 of 552

Largest Insider Buys in Sector

ALT Stock Price History Chart

ALT Stock Performance

About Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Insider Activity of Altimmune, Inc.

Over the last 12 months, insiders at Altimmune, Inc. have bought $0 and sold $110,547 worth of Altimmune, Inc. stock.

On average, over the past 5 years, insiders at Altimmune, Inc. have bought $7.62M and sold $718,037 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 300 shares for transaction amount of $863 was made by Drutz David (director) on 2023‑08‑15.

List of Insider Buy and Sell Transactions, Altimmune, Inc.

2024-08-19Saledirector
16,011
0.0206%
$6.90$110,547-7.69%
2023-08-15Purchasedirector
300
0.0006%
$2.88$863+149.13%
2023-03-24PurchaseChief Financial Officer
10,000
0.0213%
$4.31$43,140-5.32%
2023-03-23PurchaseChief Medical Officer
10,000
0.0215%
$4.22$42,200-2.39%
2023-03-23Purchasedirector
9,000
0.0195%
$4.27$38,430-2.39%
2022-12-22Saledirector
20,000
0.0383%
$15.01$300,268-73.88%
2022-08-30SalePresident and CEO
20,000
0.0429%
$20.02$400,322-47.31%
2022-08-12SalePresident and CEO
15,000
0.0264%
$15.06$225,890-39.75%
2022-08-12Saledirector
2,714
0.0048%
$15.00$40,710-39.75%
2022-07-01SaleChief Scientific Officer
10,182
0.022%
$12.00$122,184+0.62%
2022-06-29SaleChief Scientific Officer
5,462
0.0117%
$12.00$65,546-3.74%
2022-06-27SaleChief Scientific Officer
37,352
0.0803%
$12.00$448,254-3.40%
2022-06-27Sale
17,610
0.0371%
$11.75$206,944-3.40%
2022-06-15Purchase
1,000
0.002%
$8.00$8,000+36.66%
2022-05-24Purchase
1,200
0.0024%
$4.50$5,400+140.89%
2022-02-28SaleChief Medical Officer
30,000
0.0692%
$7.52$225,600+52.50%
2021-03-01Saledirector
6,000
0.0151%
$16.08$96,480-28.09%
2020-12-10Purchasedirector
2,000
0.0076%
$11.99$23,980+5.50%
2020-12-01Saledirector
1,227
0.0047%
$13.54$16,614-6.30%
2020-11-30Saledirector
2,500
0.0096%
$12.00$30,000+6.26%

Insider Historical Profitability

<0.0001%
Drutz Daviddirector
41958
0.059%
$8.5961+23.34%
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.10 percent owner
6626403
9.3166%
$8.5913<0.0001%
EVNIN LUKE10 percent owner
6347614
8.9246%
$8.5920
MPM BIOVENTURES III LLC10 percent owner
6347614
8.9246%
$8.5920
Venrock Healthcare Capital Partners III, L.P.10 percent owner
4500000
6.3269%
$8.5940+64.5%
VELOCITY PHARMACEUTICAL HOLDINGS LLC10 percent owner
1687250
2.3722%
$8.5902
SCHAFFER DERACE Ldirector
589453
0.8288%
$8.59415<0.0001%
KINLEY MATTHEW P
541000
0.7606%
$8.59110
WRIGHT DAVID PPresident and CEO
399500
0.5617%
$8.5980+149.96%
PAPPAJOHN JOHNdirector
394044
0.554%
$8.59153
Enright WilliamPresident and CEO
365839
0.5144%
$8.5910<0.0001%
HEALTHCARE VENTURES VII LP10 percent owner
250000
0.3515%
$8.5910
Garg Vipin KPresident and CEO
236797
0.3329%
$8.5912+40.29%
RICHMAN ERIC Idirector
176822
0.2486%
$8.5923
Riddle Valerie DSVP, Medical Director
44436
0.0625%
$8.5903
Harris Matthew ScottChief Medical Officer
33311
0.0468%
$8.5912<0.0001%
SAYARE MITCHELdirector
32650
0.0459%
$8.5920<0.0001%
CHANG LINDA LSVP, CFO & Secretary
30000
0.0422%
$8.5911
St Peter Stevendirector
25000
0.0351%
$8.5910<0.0001%
Eisenstadt Richard IChief Financial Officer
22010
0.0309%
$8.5910<0.0001%
Runge Jeffrey W.director
20000
0.0281%
$8.5920
FUERST THOMAS RICHARDSVP, Chief Scientific Officer
15000
0.0211%
$8.5920
Karp Jordan PSVP, General Counsel
10000
0.0141%
$8.5910
Schafer Klausdirector
8900
0.0125%
$8.5911+5.5%
Hodges Philipdirector
8731
0.0123%
$8.5903
Pisano Waynedirector
8498
0.0119%
$8.5912<0.0001%
Roberts M ScotChief Scientific Officer
8305
0.0117%
$8.5913<0.0001%
GILL JOHNdirector
2771
0.0039%
$8.5912<0.0001%
Price KevinPresident-Pharmathene UK, Ltd.
2500
0.0035%
$8.5910+153.68%
Jorkasky Diane
0
0%
$8.5901

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
State Street$88.05M12.28.65M+752.53%+$77.72M<0.01
BlackRock$41.15M5.74.04M-0.06%-$25,256.58<0.01
The Vanguard Group$31.85M4.413.13M-12.41%-$4.51M<0.01
Tang Capital Management, LLC$28M3.882.75M0%+$00.11
Morgan Stanley$22.52M3.122.21M+112.5%+$11.92M<0.01
Ameriprise Financial$17.4M2.411.71M-59.14%-$25.19M0.01
Millennium Management LLC$16.19M2.241.59M+813.14%+$14.41M0.01
Geode Capital Management$12.59M1.741.24M+3.63%+$440,547.42<0.01
Alger$10.11M1.4993,516+204.15%+$6.79M0.05
Susquehanna International Group$9.33M1.29916,254+24.96%+$1.86M0.01
Nuveen$9.29M1.29913,000-47.14%-$8.29M<0.01
Portolan Capital Management$9.03M1.25887,255New+$9.03M0.7
Rafferty Asset Management Llc$8.99M1.25882,628New+$8.99M0.03
Goldman Sachs$8.77M1.22861,415+64.31%+$3.43M<0.01
Readystate Asset Management Lp$8.41M1.17825,800New+$8.41M0.47
Citigroup$7.56M1.05742,913+9,704.84%+$7.49M0.01
Tupelo Capital Management LLC$5.77M0.8567,219+183.61%+$3.74M0.14
Bank of America$5.09M0.71499,872+1,752.96%+$4.81M<0.0001
Northern Trust$5.03M0.7493,968+4.25%+$205,015.05<0.01
UBS$4.99M0.69490,001+741.06%+$4.4M<0.01
Farallon Capital$4.78M0.66470,000+1,282.35%+$4.44M0.03
Jacobs Levy Equity Management$4.4M0.61432,666+0.07%+$3,308.500.02
BBR Partners$3.65M0.51358,513New+$3.65M0.3
D. E. Shaw & Co.$3.61M0.5354,350+22.3%+$657,872.32<0.01
Ensign Peak Advisors Inc$3.33M0.46326,7770%+$00.01
Group One Trading$3.15M0.44309,459-43.47%-$2.42M0.04
Moody Aldrich Partners, LLC$3.13M0.43307,318New+$3.13M0.53
Timelo Investment Management Inc.$2.99M0.42294,095-63.65%-$5.24M5.48
Voya Investment Management LLC$2.93M0.41288,273+1,305.93%+$2.73M<0.01
Ardsley Advisory Partners$2.8M0.39275,000-19.36%-$671,880.000.41
Beirne Wealth Consulting Services, LLC (BWC)$2.78M0.39272,800-10.2%-$315,580.001.19
GHOST TREE CAPITAL LLC$2.54M0.35250,000New+$2.54M0.03
Dimensional Fund Advisors$2.39M0.33234,730-10.24%-$272,701.79<0.01
Woodline Partners LP$2.18M0.3214,245New+$2.18M0.02
Schroder Investment Management Group$1.94M0.27190,824New+$1.94M<0.01
BNY Mellon$1.93M0.27189,654-1.01%-$19,688.12<0.0001
Imc Chicago Llc$1.69M0.23165,607+25.71%+$344,786.370.01
Wellington Management Company$1.6M0.22156,914New+$1.6M<0.0001
Lynwood Capital Management Inc.$1.53M0.21150,000New+$1.53M14.1
Simplex Trading Llc$1.49M0.21146,259+124.56%+$825,374.600.04
Charles Schwab$1.45M0.2142,7050%+$0<0.0001
Profund Advisors Llc$1.37M0.19134,842New+$1.37M0.04
Raymond James Associates$1.23M0.17121,137New+$1.23M<0.01
Campbell Co Investment Adviser Llc$1.12M0.16110,213New+$1.12M0.09
Pennant Capital Management Llc$1.12M0.16109,8000%+$00.18
Swiss National Bank$1.08M0.15106,000New+$1.08M<0.01
OMERS$1.06M0.15104,600New+$1.06M0.01
Silvercrest Asset Management Group Inc$1.05M0.15103,5000%+$00.01
Jane Street Capital$1.03M0.14101,577-82.5%-$4.87M<0.01
Schonfeld Group$1.03M0.14101,426-24.87%-$341,783.090.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.